Silk Road Medical Names Rick Anderson to Board of Directors
October 01 2020 - 4:05PM
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on
reducing the risk of stroke and its devastating impact, today
announced that medical device industry veteran Rick Anderson has
joined its board of directors.
Anderson brings over 30 years of senior executive leadership
experience in the medical device industry. He is the Chairman and
Managing Director of Revival Healthcare Capital, a sustainable,
high impact investment firm that specializes in medical devices and
diagnostics. He currently serves on the boards of Apollo
Endosurgery (Nasdaq: APEN) and Cardiologs, a leading cardiovascular
artificial intelligence company; on the Executive Advisory Board of
LEK Consulting, a leading healthcare consulting firm; and as an
Independent Director of ConvaTec Group Plc, a FTSE 250 company
specializing in medical products and related technologies. Anderson
previously served as Chairman of the Board and CEO of ConvaTec
Group Plc, where in his one-year interim roles he created
additional shareholder value through his “Pivot to Growth” strategy
and new $150 million transformation plan. He also previously served
as Chairman of the Board for Cardiva Medical, IDEV Technologies,
and Tryton Medical, and served as Director on the boards of
Intersect ENT and multiple other medical device companies.
Prior to founding Revival, Anderson served as a Managing
Director at PTV Healthcare Capital, a venture capital and private
equity firm specializing in the healthcare and life science
industries. He also served as the Company Group Chairman of Johnson
& Johnson and Worldwide Franchise Chairman of Cordis
Corporation. Anderson was a key architect behind the launch of the
world’s first drug-eluting stent, the CYPHER® Sirolimus-eluting
Coronary Stent. Anderson holds a B.B.A. in Marketing from
Mississippi State University.
“Rick is an acclaimed leader in the medical device industry with
notable experience as a board member working to drive growth,” said
Erica Rogers, Chief Executive Officer. “I look forward to his
insight and guidance as we continue to advance TCAR’s role in
preventing stroke.”
“Silk Road Medical has revolutionized the treatment of carotid
artery disease and I am honored to be joining the Board of
Directors,” said Anderson. “I am excited to be working with this
wonderful team to continue to expand their tremendous market
opportunities.”
About Silk Road Medical Silk
Road Medical, Inc. (NASDAQ: SILK), is a medical device company
located in Sunnyvale, California, that is focused on reducing
the risk of stroke and its devastating impact. The company has
pioneered a new approach for the treatment of carotid artery
disease called TransCarotid Artery Revascularization (TCAR). TCAR
is a clinically proven procedure combining surgical principles of
neuroprotection with minimally invasive endovascular techniques to
treat blockages in the carotid artery at risk of causing a stroke.
For more information on how Silk Road Medical is delivering
brighter patient outcomes through brighter clinical thinking, visit
www.silkroadmed.com and connect on Twitter, LinkedIn and
Facebook.
About Revival Healthcare CapitalRevival
Healthcare Capital is a sustainable, high impact investment
platform specializing in the medical device and diagnostic sectors
of healthcare. To learn more, visit rvlhc.com.
Investors:Lynn Lewis or Caroline PaulGilmartin
Groupinvestors@silkroadmed.com
Media:Michael FanucchiSilk Road
Medicalmfanucchi@silkroadmed.com
Apollo Endosurgery (NASDAQ:APEN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Apollo Endosurgery (NASDAQ:APEN)
Historical Stock Chart
From Jan 2024 to Jan 2025